Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talazoparib + Belinostat in Advanced Solid Tumors
NCT04703920Phase 1Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Mar 2021
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib and belinostat in breast cancer, metastatic castration-resistant prostate cancer (mCRPC), Malignant ovarian neoplasm (OC) and 1 more, sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Dose Limiting Toxicities at 10 weeks. Started Mar 2021; status: completed.
02
Drugs
talazoparibbelinostat
03
Conditions
breast cancermetastatic castration-resistant prostate cancer (mCRPC)Malignant ovarian neoplasm (OC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04703920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04703920.